IDXGD (Interpace Biosciences) Cyclically Adjusted FCF per Share: $-29.40 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IDXGD Interpace Biosciences Inc IDXGD
41 GF Score
Price $7.62
GF Value $0.20
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Interpace Biosciences Cyclically Adjusted FCF per Share?

Interpace Biosciences IDXGD +5.08% 41 Cyclically Adjusted FCF per Share is $-29.40 as of Jun. 2026. GuruFocus rates IDXGD with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Interpace Biosciences's adjusted free cash flow per share for the three months ended in Jun. 2026 was $0.007. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-29.40 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 43.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 27.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Interpace Biosciences was 43.40% per year. The lowest was -269.80% per year. And the median was -0.25% per year.

As of today (2026-08-29), Interpace Biosciences's current stock price is $7.618. Interpace Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $-29.40. Interpace Biosciences's Cyclically Adjusted Price-to-FCF of today is .


Interpace Biosciences  (OTCPK:IDXGD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Interpace Biosciences Cyclically Adjusted FCF per Share Related Terms


Interpace Biosciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Interpace Biosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Interpace Biosciences Cyclically Adjusted FCF per Share Chart

Interpace Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -297.52 -266.73 -251.00 -134.45 -48.40

Interpace Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -97.92 -74.62 -48.40 -34.02 -29.40

IDXGD vs PRPO, ADVB, BIOQ: Cyclically Adjusted FCF per Share Comparison

For the Diagnostics & Research subindustry, Interpace Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences Cyclically Adjusted Price-to-FCF vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Cyclically Adjusted Price-to-FCF falls into.


IDXGD
41GF Score
Interpace Biosciences Inc IDXGD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Interpace Biosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Interpace Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.007/333.9520*333.9520
=0.007

Current CPI (Jun. 2026) = 333.9520.

Interpace Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -37.389 241.428 -51.718
201612 -26.757 241.432 -37.011
201703 -47.148 243.801 -64.582
201706 -22.917 244.955 -31.243
201709 -9.778 246.819 -13.230
201712 -4.271 246.524 -5.786
201803 -4.585 249.554 -6.136
201806 -4.565 251.989 -6.050
201809 -3.691 252.439 -4.883
201812 -3.375 251.233 -4.486
201903 -4.228 254.202 -5.554
201906 -6.371 256.143 -8.306
201909 -6.319 256.759 -8.219
201912 -8.379 256.974 -10.889
202003 -8.891 258.115 -11.503
202006 0.556 257.797 0.720
202009 -7.082 260.280 -9.087
202012 -1.960 260.474 -2.513
202103 -6.120 264.877 -7.716
202106 -2.218 271.696 -2.726
202109 -0.812 274.310 -0.989
202112 -1.455 278.802 -1.743
202203 -1.512 287.504 -1.756
202206 -3.528 296.311 -3.976
202209 -3.873 296.808 -4.358
202212 -0.553 296.797 -0.622
202303 1.239 301.836 1.371
202306 0.348 305.109 0.381
202309 1.103 307.789 1.197
202312 1.137 306.746 1.238
202403 -0.098 312.332 -0.105
202406 1.372 314.175 1.458
202409 1.801 315.301 1.908
202412 1.196 315.605 1.266
202503 0.223 319.799 0.233
202506 0.588 322.561 0.609
202509 0.350 324.800 0.360
202512 0.386 324.054 0.398
202603 0.026 330.213 0.026
202606 0.007 333.952 0.007

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-29.40 mean?
Interpace Biosciences (IDXGD) has a Cyclically Adjusted FCF per Share of $-29.40 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Interpace Biosciences and its competitors.
Is Interpace Biosciences' Cyclically Adjusted FCF per Share too high?
Interpace Biosciences' current Cyclically Adjusted FCF per Share is $-29.40. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Cyclically Adjusted FCF per Share compare to PRPO and ADVB?
Interpace Biosciences' Cyclically Adjusted FCF per Share of $-29.40 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted FCF per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Interpace Biosciences and its competitors. Interpace Biosciences's current Cyclically Adjusted FCF per Share is $-29.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXGD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $7.62 — trading 3709% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-29.40. Interpace Biosciences' overall GF Score™ is 41/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Interpace Biosciences (IDXGD), the current Cyclically Adjusted FCF per Share is $-29.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Interpace Biosciences (IDXGD) Overvalued in 2026?

Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued. The current stock price of $7.62 is trading 3709% above its estimated GF Value™ of $0.20. GuruFocus considers Interpace Biosciences to be Significantly Overvalued.

Key valuation signals for IDXGD:

  • Cyclically Adjusted FCF per Share: $-29.40
  • GF Value™: $0.20 vs. price of $7.62 (3709% above fair value)
  • GF Score™: 41/100 with 8 warning signs

No single metric tells the full story. See the IDXGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Interpace Biosciences Business Description

Other Exchanges PF42:Germany
Address 2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score

Get the complete analysis for IDXGD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.62
Price
$0.20
GF Value